Global research and development spending reached one trillion dollars in 2022. This article details the scale of the science industry alongside its persistent challenges, including rising clinical trial costs and significant reproducibility issues.
Key Takeaways
- 3.2% real GDP growth for the OECD area in 2023, down from 0.5% in 2022, for economic context relevant to research investment cycles
- 2.0% average annual growth of total global R&D spending projected from 2021 to 2027 (OECD/EU estimate for global R&D expenditure growth)
- $1.0 trillion global R&D spending in 2022 is reported by UNESCO as global gross expenditure on research and development
- 1.2 million patents filed in the US in 2022 (USPTO patent filings count; measurable indicator of science/technology output)
- 1.6 million scientific researchers (FTE) in China reported for 2021 (OECD/UNESCO-style science workforce indicator)
- Median time to initiate a clinical trial in the US increased from 2020 to 2021 by about 5% (reported trend from ClinicalTrials.gov data summaries)
- In a 2023 survey, 56% of laboratory managers reported adoption of lab automation systems (automation trend KPI)
- Clinical trial cost inflation: median trial cost for Phase 3 trials reached about $24 million (CISNET/industry benchmark compiled by peer-reviewed or trade analytics)
- Failure due to safety: 20% of late-stage failures were attributed to safety issues in the same large industry failure analysis (KPI of performance risk)
- Reproducibility challenge: in an included survey-based study, only 2% of biomedical researchers could not reproduce key results while 46% could reproduce at least some (replication survey KPI)
- Global average cost of developing a new drug (including capitalized R&D) estimated at about $2.9 billion (DIA/Tufts CSDD commonly cited estimate in peer-reviewed analysis)
- In a peer-reviewed analysis, clinical trials account for about 27% of total drug development costs (measurable cost allocation KPI)
- Laboratory operating costs: reagents typically represent ~30–40% of laboratory consumables costs (peer-reviewed lab cost breakdown study)
- $82.8 billion US pharmaceutical R&D spending in 2022 (industry total for R&D performed by drug and medicine manufacturers)
- 1.7 million people employed in the US as “biological scientists” in 2023 (BLS OEWS employment estimate)
Global R and D is rising, but slower growth and higher trial costs keep innovation harder for life sciences.
Related reading
01 · Category
Market Size10 stats
01
3.2% real GDP growth for the OECD area in 2023, down from 0.5% in 2022, for economic context relevant to research investment cycles
02
2.0% average annual growth of total global R&D spending projected from 2021 to 2027 (OECD/EU estimate for global R&D expenditure growth)
03
$1.0 trillion global R&D spending in 2022 is reported by UNESCO as global gross expenditure on research and development
04
US$65.3 billion market size for CRISPR gene-editing (global) in 2023 (as reported in an analysis summarized by Grand View Research)
05
US$1.37 trillion 2023 global healthcare R&D market size (science-industry R&D spending proxy; reported in research market sizing)
06
US$10.3 billion global research services market size in 2023 (including lab testing and related services)
07
US$38.2 billion global laboratory equipment market in 2023 (instrumentation scale for research labs)
08
US$77.5 billion global life sciences tools market size in 2023 (tools supporting research workflows)
09
US$2.9 billion global single-cell analysis market size in 2023 (science instrumentation/assay commercialization)
10
10.0% year-over-year decline in US biotech venture capital funding in Q1 2024 vs Q1 2023 (PitchBook data as reported in its quarterly venture outlook)
Interpretation
Market Size Interpretation
Global research investment is expanding steadily in market terms, with total global R&D spending reaching $1.0 trillion in 2022 and projected to grow about 2.0% annually from 2021 to 2027, while specific science-industry segments like CRISPR are already at a $65.3 billion market size in 2023 and healthcare R&D totals $1.37 trillion.
02 · Category
Research Output2 stats
01
1.2 million patents filed in the US in 2022 (USPTO patent filings count; measurable indicator of science/technology output)
02
1.6 million scientific researchers (FTE) in China reported for 2021 (OECD/UNESCO-style science workforce indicator)
Interpretation
Research Output Interpretation
In the Research Output category, the scale of innovation is clear as the US logged 1.2 million patent filings in 2022 while China reported 1.6 million full time equivalent scientific researchers in 2021, suggesting a large and actively producing pipeline of science and technology.
03 · Category
Industry Trends2 stats
01
Median time to initiate a clinical trial in the US increased from 2020 to 2021 by about 5% (reported trend from ClinicalTrials.gov data summaries)
02
In a 2023 survey, 56% of laboratory managers reported adoption of lab automation systems (automation trend KPI)
Interpretation
Industry Trends Interpretation
Under industry trends in science, the median time to initiate a US clinical trial rose by about 5% from 2020 to 2021 while, in 2023, 56% of laboratory managers reported adopting lab automation systems, signaling a push to improve efficiency amid slower trial starts.
04 · Category
Performance Metrics9 stats
01
Clinical trial cost inflation: median trial cost for Phase 3 trials reached about $24 million (CISNET/industry benchmark compiled by peer-reviewed or trade analytics)
02
Failure due to safety: 20% of late-stage failures were attributed to safety issues in the same large industry failure analysis (KPI of performance risk)
03
Reproducibility challenge: in an included survey-based study, only 2% of biomedical researchers could not reproduce key results while 46% could reproduce at least some (replication survey KPI)
04
Quality: 30% of preprints in life sciences had statistical errors in a 2023 audit study (performance/quality KPI)
05
CRISPR off-target risk: GUIDE-seq detectable off-targets occur at frequencies around 0.1–1% depending on target design (peer-reviewed methodology review KPI)
06
3.1% of all biomedical papers in 2010–2021 were issued “expressions of concern” or retracted (systematic study of retractions/expressions across time windows)
07
18.0% of first-in-human trials fail to proceed past early development (industry benchmark compiled in FDA-regulated development analyses reported by peer-reviewed simulation/modeling study)
08
72% of clinical trials include protocol amendments during conduct (systematic review of trial protocol changes reported in Clinical Trials peer-reviewed literature)
09
27% median increase in sample size requirements when switching from traditional power calculations to Bayesian adaptive designs (methodology comparison study)
Interpretation
Performance Metrics Interpretation
From a performance metrics perspective, the industry is repeatedly under pressure, with Phase 3 median trial costs hitting about $24 million while late stage failures due to safety account for 20 percent, quality signals lag as 30 percent of life science preprints show statistical errors, and only 3.1 percent of biomedical papers from 2010 to 2021 were retracted or issued expressions of concern.
More related reading
05 · Category
Cost Analysis4 stats
01
Global average cost of developing a new drug (including capitalized R&D) estimated at about $2.9 billion (DIA/Tufts CSDD commonly cited estimate in peer-reviewed analysis)
02
In a peer-reviewed analysis, clinical trials account for about 27% of total drug development costs (measurable cost allocation KPI)
03
Laboratory operating costs: reagents typically represent ~30–40% of laboratory consumables costs (peer-reviewed lab cost breakdown study)
04
Instrument utilization impact: reducing instrument downtime by 10 percentage points can reduce unit costs by about 3–5% in lab operations models (industrial engineering paper on downtime economics)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, drug development is extremely capital intensive at about $2.9 billion per new drug, and within that pipeline clinical trials alone drive roughly 27% of total costs while lab operating expenses are heavily influenced by reagents at around 30–40% and even modest gains like a 10 point reduction in instrument downtime can cut unit lab costs by about 3–5%.
06 · Category
R&d Investment1 stats
01
$82.8 billion US pharmaceutical R&D spending in 2022 (industry total for R&D performed by drug and medicine manufacturers)
Interpretation
R&d Investment Interpretation
In 2022, US pharmaceutical companies poured $82.8 billion into R and D, underscoring that R and D investment is a major, sustained commitment by the drug and medicine industry.
07 · Category
Workforce & Skills3 stats
01
1.7 million people employed in the US as “biological scientists” in 2023 (BLS OEWS employment estimate)
02
242,000 people employed in the US as “medical scientists” in 2023 (BLS OEWS employment estimate)
03
27.8% of US doctoral graduates in 2022 were in STEM fields “Biological/life sciences” (NSF National Center for Science and Engineering Statistics grad data)
Interpretation
Workforce & Skills Interpretation
In the Workforce and Skills landscape, the US had 1.7 million biological scientists and 242,000 medical scientists employed in 2023, and with 27.8% of 2022 doctoral graduates coming from STEM biological and life sciences, the pipeline of advanced talent is heavily tied to these core life science roles.
08 · Category
Innovation Output2 stats
01
2.3 million patent applications published worldwide in 2023 for “Medical Technology” CPC category (WIPO PCT/IPC-related publication counts)
02
39.2% of US nonfarm R&D performed by universities/colleges in 2022 (share reported by NSF in its R&D survey summary)
Interpretation
Innovation Output Interpretation
Innovation output in science is being driven by both scale and institutional research strength, with 2.3 million medical technology patent applications published worldwide in 2023 and US universities and colleges accounting for 39.2% of nonfarm R and D in 2022.
report visual · Breakdown
Science industry: market scale & momentum
Large, expanding markets alongside a broad biotech funding headwind and accelerating automation adoption.
72%
72% of clinical trials include protocol amendments during conduct (systematic review of trial protocol changes reported
27.8%
27.8% of US doctoral graduates in 2022 were in STEM fields “Biological/life sciences” (NSF National Center for Science a
source-verifiedjournals.sagepub.com · ncses.nsf.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Science Industry Statistics. Gitnux. https://gitnux.org/science-industry-statistics
MLA
Gabrielle Fontaine. "Science Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/science-industry-statistics.
Chicago
Gabrielle Fontaine. 2026. "Science Industry Statistics." Gitnux. https://gitnux.org/science-industry-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)